• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

作者信息

Fine B M, Amler L

机构信息

Genentech, Inc., South San Francisco, California, USA.

出版信息

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.

DOI:10.1038/clpt.2009.9
PMID:19295504
Abstract
摘要

相似文献

1
Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.肿瘤药物研发中的预测性生物标志物：治疗行业视角
Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.
2
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.机制驱动的肿瘤药物研发中生物标志物和替代终点的原理
Clin Cancer Res. 2004 Jun 1;10(11):3885-96. doi: 10.1158/1078-0432.CCR-03-0785.
3
SRC as a potential therapeutic target in solid tumor oncology.Src作为实体肿瘤肿瘤学中的潜在治疗靶点。
Clin Adv Hematol Oncol. 2004 Jul;2(7):435-7.
4
Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.早期肿瘤药物研发中的药代动力学和药效学生物标志物
Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.
5
Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.
Expert Rev Anticancer Ther. 2005 Aug;5(4):727-35. doi: 10.1586/14737140.5.4.727.
6
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.表皮生长因子受体靶向治疗的临床试验设计与终点：对药物研发及临床实践的启示
Clin Cancer Res. 2003 May;9(5):1579-89.
7
Targeted therapies: aiming for the bull's-eye.靶向治疗：瞄准靶心。
ONS Connect. 2007 Jul;22(7):8-12.
8
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.癌症治疗中的表皮生长因子受体抑制剂：进展、挑战与机遇
Anticancer Drugs. 2009 Nov;20(10):851-5. doi: 10.1097/CAD.0b013e3283330590.
9
Foreword.前言。
Curr Probl Cancer. 2009 Jul-Aug;33(4):244. doi: 10.1016/j.currproblcancer.2009.10.001.
10
American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.
IDrugs. 2009 Jun;12(6):335-8.

引用本文的文献

1
Hypoxia-targeted drug delivery.缺氧靶向药物递送。
Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a.
2
Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses.基于芯片的纳升液相色谱-飞行时间质谱是一种用于大规模高通量分析的高稳定性技术。
Anal Bioanal Chem. 2013 May;405(14):4953-8. doi: 10.1007/s00216-013-6908-z. Epub 2013 Mar 23.
3
Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.美国食品和药物管理局的肿瘤药物开发和全身抗癌治疗的批准。
Oncologist. 2013;18(1):104-11. doi: 10.1634/theoncologist.2012-0235. Epub 2012 Dec 20.
4
Quantifying factors for the success of stratified medicine.量化分层医学成功的因素。
Nat Rev Drug Discov. 2011 Oct 31;10(11):817-33. doi: 10.1038/nrd3557.
5
Predictive biomarkers: a paradigm shift towards personalized cancer medicine.预测性生物标志物：个性化癌症医学的范式转变。
Nat Rev Clin Oncol. 2011 Aug 23;8(10):587-96. doi: 10.1038/nrclinonc.2011.121.
6
Molecular therapy drives patient-centric health care paradigms.分子疗法推动以患者为中心的医疗保健模式。
Clin Transl Sci. 2010 Aug;3(4):170-1. doi: 10.1111/j.1752-8062.2010.00203.x.
7
Bayesian adaptive randomization designs for targeted agent development.贝叶斯适应性随机分组设计在靶向药物研发中的应用
Clin Trials. 2010 Oct;7(5):584-96. doi: 10.1177/1740774510373120. Epub 2010 Jun 22.
8
The evolving role of mass spectrometry in cancer biomarker discovery.质谱在癌症生物标志物发现中的角色演变
Cancer Biol Ther. 2009 Jun;8(12):1083-94. doi: 10.4161/cbt.8.12.8634. Epub 2009 Jun 6.